Oruka Therapeutics, Inc.
ORKA
$111.04
$2.922.70%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -132.89M | -116.25M | -105.43M | -109.24M | -107.59M |
| Total Depreciation and Amortization | 134.00K | 110.00K | 83.00K | 73.50K | 64.50K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 25.99M | 23.21M | 19.70M | 20.37M | 21.64M |
| Change in Net Operating Assets | 5.84M | 2.01M | -2.56M | -891.30K | -10.02M |
| Cash from Operations | -100.92M | -90.92M | -88.21M | -89.69M | -95.91M |
| Capital Expenditure | -235.00K | -269.00K | -209.00K | -181.20K | -253.20K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -569.62M | -153.78M | -96.54M | -434.51M | -312.16M |
| Cash from Investing | -569.86M | -154.05M | -96.75M | -434.69M | -312.41M |
| Total Debt Issued | -- | -- | -- | 2.27M | 2.27M |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 873.85M | 210.92M | 170.32M | 207.82M | 460.07M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | 266.50K | 266.50K |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 1.59M |
| Cash from Financing | 873.85M | 210.92M | 170.32M | 210.36M | 464.19M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 203.07M | -34.05M | -14.64M | -314.02M | 55.87M |